Rapid Micro Biosystems, Inc. (RPID)
| Market Cap | 39.38M -69.6% |
| Revenue (ttm) | 35.18M +16.1% |
| Net Income | -51.20M |
| EPS | -1.11 |
| Shares Out | 50.16M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 35,058 |
| Open | 0.7850 |
| Previous Close | 0.7800 |
| Day's Range | 0.7735 - 0.8124 |
| 52-Week Range | 0.7600 - 4.9400 |
| Beta | 1.51 |
| Analysts | Strong Buy |
| Price Target | 5.75 (+632.48%) |
| Est. Earnings | Nov 10, 2026 |
About RPID
Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biologics, medical devices, and personal care products in the United States, Switzerland, Germany, Japan, and internationally. The company offers Growth Direct platform, which includes growth direct system, proprietary consumables, lab information management system connection software, and customer support and validation services. Its platform automates and modernizes the antiquat... [Read more]
Financial Performance
In 2025, Rapid Micro Biosystems's revenue was $33.59 million, an increase of 19.74% compared to the previous year's $28.05 million. Losses were -$47.12 million, 0.50% more than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for RPID stock is "Strong Buy." The 12-month stock price target is $5.75, which is an increase of 632.48% from the latest price.
News
Rapid Micro Biosystems to Participate at the PDA Pharmaceutical Microbiology Conference 2026
LEXINGTON, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation so...
Rapid Micro Biosystems initiated with a Buy at Roth Capital
Roth Capital initiated coverage of Rapid Micro Biosystems (RPID) with a Buy rating and $3 price target The company provides exposure to the automation of pharmaceutical microbial quality control, a…
Rapid Micro Biosystems Transcript: Small-Cap Virtual Conference
Revenue is projected to grow 20% annually, driven by a recurring revenue model and expanding system placements, especially among top pharma companies. Gross margins are expected to rise from 20% in 2024 to over 50% by 2028, supported by a key partnership with Merck MilliporeSigma and disciplined capital management.
Rapid Micro Biosystems Slides: Small-Cap Virtual Conference
Rapid Micro Biosystems has posted slides in relation to its latest quarterly earnings report, which was published on September 24, 2026.
Rapid Micro Biosystems to Participate in Upcoming Investor Conferences
LEXINGTON, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation s...
Rapid Micro Biosystems Earnings Call Transcript: Q2 2026
Second quarter revenue grew 11% year-over-year to $8.1 million, with record consumables and service margins. Full-year guidance is reaffirmed, margin expansion is on track, and the MilliporeSigma partnership is expected to drive further growth.
Rapid Micro Biosystems Earnings release: Q2 2026
Rapid Micro Biosystems released its Q2 2026 earnings on August 7, 2026, summarizing the period's financial results.
Rapid Micro Biosystems Quarterly report: Q2 2026
Rapid Micro Biosystems has published its Q2 2026 quarterly earnings report on August 7, 2026.
Rapid Micro Biosystems reports Q2 EPS (27c), consensus (24c)
Reports Q2 revenue $8.05M, consensus $7.88M. “Our second quarter results reflect continued execution against the strategic and financial priorities we outlined at the beginning of the year,” said Robe...
Rapid Micro Biosystems backs FY26 revenue view $37M-$41M, consensus $39.3M
Raises FY26 system validation view to at least 27 validations from 25 validations. Spignesi continued, “As we look to the second half of 2026, we remain encouraged by strong customer…
Rapid Micro Biosystems Reports Second Quarter 2026 Financial Results
Reports second quarter 2026 total revenue of $8.1 million , representing 11% growth compared to the second quarter of 2025 Achieved a significant milestone with the 200th Growth Direct system placed ...
Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LEXINGTON, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation so...
Rapid Micro Biosystems to Announce Second Quarter 2026 Financial Results on August 7, 2026
LEXINGTON, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation so...
Rapid Micro Biosystems Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
LEXINGTON, Mass., June 10, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation so...
Rapid Micro Biosystems price target lowered to $5 from $8 at KeyBanc
KeyBanc lowered the firm’s price target on Rapid Micro Biosystems (RPID) to $5 from $8 and keeps an Overweight rating on the shares. The firm is updating its model to…
Rapid Micro Biosystems price target lowered to $7 from $8 at Lake Street
Lake Street lowered the firm’s price target on Rapid Micro Biosystems (RPID) to $7 from $8 and keeps a Buy rating on the shares after the company announced an underwritten…
Rapid Micro Biosystems Transcript: AGM 2026
The meeting addressed director elections and auditor ratification, with both proposals approved by shareholders. Voting procedures and governance practices were emphasized, and no questions were raised by stakeholders.
Rapid Micro Biosystems Announces Pricing of Up to Approximately $32 Million Underwritten Offering
Bain Capital Life Sciences and Armistice Capital are investing approximately $9.8 million, with the potential of up to approximately $32 million in the event the warrants offered in this offering are ...
Rapid Micro Biosystems reports Q1 EPS (31c), consensus (25c)
Reports Q1 revenue $8.0M, consensus $7.6M. Cash, cash equivalents, short-term investments, and restricted cash were approximately $23M as of March 31. “Our first quarter results reflect strong and con...
Rapid Micro Biosystems Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 11% year-over-year to $8 million, driven by strong system placements and recurring revenue, with record consumables growth and improved product margins. The company reaffirmed its 2026 revenue guidance and continues to expand globally, especially in Asia-Pacific.
Rapid Micro Biosystems Earnings release: Q1 2026
Rapid Micro Biosystems released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Rapid Micro Biosystems Quarterly report: Q1 2026
Rapid Micro Biosystems has published its Q1 2026 quarterly earnings report on May 13, 2026.
Rapid Micro Biosystems Reports First Quarter 2026 Financial Results
LEXINGTON, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation sol...
Rapid Micro Biosystems Slides: Corporate presentation
Rapid Micro Biosystems has posted slides in relation to its latest quarterly earnings report, which was published on May 13, 2026.
Rapid Micro Biosystems to Announce First Quarter 2026 Financial Results on May 13, 2026
LEXINGTON, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation sol...